Targeting the WntBeta-catenin Pathway in Liver Cancer
Targeting the WntBeta-catenin Pathway in Liver Cancer
批准号:
8096724
负责人:
Michael D Thompson
金额:
$4.5万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-07-01 至 2012-05-31
关键词:
AddressAffectAflatoxinsAlbuminsAppearanceAttenuatedBindingCancer EtiologyCellular biologyCessation of lifeChemopreventionCyclin D1DataDevelopmentDiethylnitrosamineDiseaseEnhancersEtodolacExhibitsExposure toGene MutationGenesGlutamate-Ammonia LigaseGrowthHepaticHepatocarcinogenesisHepatocyteHistologyInterferonsLeadLiverLiver neoplasmsMalignant NeoplasmsMalignant neoplasm of liverModelingMolecularMolecular BiologyMorphologyMusMutateMutationNatural regenerationNitrosaminesNuclearPathogenesisPathway interactionsPatientsPhosphorylationPhosphorylation SitePlayPreventionPrimary carcinoma of the liver cellsProteinsResistanceRoleSerineSignal PathwaySignal TransductionSpecimenStem cellsTestingThreonineToxic Environmental SubstancesToxinTransgenic MiceUp-RegulationWild Type Mouseadenomabasec-myc Genescancer stem cellcancer therapycarcinogenesischemotherapyhuman FZD7 proteinmortalitynoveloutcome forecastoval celloverexpressionpreventprogenitorpromoterreceptorresponsestem cell populationtumortumorigenesis
中文摘要
描述(申请人提供):肝癌是全球癌症死亡的主要原因,经常与亚硝胺和黄曲霉毒素等环境毒素有关。这种疾病的分子发病机制尚不完全清楚,因此限制了成功治疗甚至阻止其发展的能力。与肝癌发生有关的一个信号通路是Wnt/(3-catenin)通路。在肝肿瘤标本中观察到的许多突变以这样或那样的方式导致该途径的异常激活,包括各种丝氨酸和苏氨酸残基的突变,这是与蛋白质蛋白酶体降解相关的重要磷酸化位点。我们推测,3-连环素的这种稳定性为肝细胞在毒素暴露后导致的发育不良条件下提供了显着的生长优势。此外,我们认为,从药理上针对这一途径可以预防和减缓肝癌的发展。为了验证这一假设,我们建立了一个过度表达(3-连环蛋白在丝氨酸45处突变)的转基因小鼠系,丝氨酸45是最终降解的关键磷酸化位点之一。在这项研究的第一个目的中,这些小鼠将暴露在二乙基亚硝胺(DEN)中,这是一种在小鼠中使用的常见肝癌致癌物,以检查肝癌的发展。我们还将研究在该模型中抑制(3-连环蛋白)用于化学预防和/或化疗的可能性。在第二个目标中,我们将探索肝脏兼性祖细胞-卵圆细胞在Hep-S45D-TG小鼠中的激活,考虑到它们作为癌症干细胞的潜在作用。再一次,我们将利用3-连环蛋白抑制来检查针对这一干细胞群体的治疗潜力。确定肝癌发生和癌症干细胞激活的关键分子可能对患有这种高死亡率疾病的患者的治疗产生重大影响。肝癌是一种使人衰弱的疾病,是全球癌症死亡的主要原因之一。3-连环素活性异常是该疾病的一个潜在病因,其确定和靶向的适用性将对肝癌的治疗产生重大影响。
英文摘要
DESCRIPTION (provided by applicant): Liver cancer is a leading cause of cancer mortality worldwide, frequently being associated with exposure to environmental toxins such as nitrosamines and aflatoxin. The molecular pathogenesis of this disease is not yet fully understood, thus limiting the ability to successfully treat or even prevent its development. One signaling pathway that has been implicated in hepatocarcinogenesis is the Wnt/(3-catenin pathway. Many mutations observed in liver tumor specimens in one way or another lead to aberrant activation of this pathway, including mutations in various serine and threonine residues which are important phosphorylation sites associated with the protein's proteasomal degradation. We hypothesize that such stabilization of 3- catenin provides the hepatocyte with a significant growth advantage during dysplastic growth conditions that result following toxin exposure. Furthermore, we believe that targeting this pathway pharmacologically can prevent and slow the development of liver cancer. To test this hypothesis we have developed a transgenic mouse line overexpressing (3-catenin mutated at Serine 45, one of the key phosphorylation sites for eventual degradation. In the first aim of this study, these mice will be exposed to diethylnitrosamine (DEN), a common hepatocarcinogen used in mice, to examine the development of liver cancer. We will also examine the potential of (3-catenin suppression in this model for chemoprevention and/or chemotherapy. In the second aim, we will explore activation of the facultative progenitor cells of the liver, oval cells, in Hep-S45D-TG mice given their potential role as cancer stem cells. Once again, we will utilize 3-catenin suppression to examine treatment potential for targeting this stem cell population. The identification of a key molecular player in liver cancer development and cancer stem cell activation could have a significant impact on therapy for patients who suffer from this high mortality disease. Liver cancer is a debilitating disease which is one of the leading causes of cancer death worldwide. The identification of a potential cause for this disease, aberrant 3-catenin activity, and the applicability of targeting this cause will have a significant impact on liver cancer therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Impact of Maternal Obesity on Offspring Non-alcoholic Fatty Liver Disease: Role of Bile Acid Homeostasis and Microbiome
-
批准号:10224187
-
项目类别:
-
资助金额:$15.93万
-
财政年份:2019
-
负责人:Michael D Thompson
-
依托单位:
Impact of Maternal Obesity on Offspring Non-alcoholic Fatty Liver Disease: Role of Bile Acid Homeostasis and Microbiome
-
批准号:10671356
-
项目类别:
-
资助金额:$6.15万
-
财政年份:2019
-
负责人:Michael D Thompson
-
依托单位:
Impact of Maternal Obesity on Offspring Non-alcoholic Fatty Liver Disease: Role of Bile Acid Homeostasis and Microbiome
-
批准号:10459354
-
项目类别:
-
资助金额:$15.93万
-
财政年份:2019
-
负责人:Michael D Thompson
-
依托单位:
Impact of Maternal Obesity on Offspring Non-alcoholic Fatty Liver Disease: Role of Bile Acid Homeostasis and Microbiome
-
批准号:9805447
-
项目类别:
-
资助金额:$16.08万
-
财政年份:2019
-
负责人:Michael D Thompson
-
依托单位:
Targeting the WntBeta-catenin Pathway in Liver Cancer
-
批准号:7922126
-
项目类别:
-
资助金额:$4.62万
-
财政年份:2008
-
负责人:Michael D Thompson
-
依托单位:
Targeting the WntBeta-catenin Pathway in Liver Cancer
-
批准号:7485471
-
项目类别:
-
资助金额:$4.6万
-
财政年份:2008
-
负责人:Michael D Thompson
-
依托单位:
海外基金